Lanadelumab - Shire

Drug Profile

Lanadelumab - Shire

Alternative Names: DX-2930; SHP 643

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dyax
  • Developer Shire
  • Class Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hereditary angioedema
  • Preclinical Diabetic macular oedema

Most Recent Events

  • 30 May 2018 Shire completes a phase I trial in Healthy volunteers in USA (SC) (NCT03401671)
  • 18 Apr 2018 The Swissmedic validates the MAA application for lanadelumab for the prevention of angioedema attacks in Hereditary angioedema
  • 18 Apr 2018 Preregistration for Hereditary angioedema (In adolescents, In adults, Prevention) in Switzerland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top